Hate exercising? Factoring in your personality type could help.
The peer-reviewed study, published Tuesday in Frontiers in Psychology, found that extroverts tend to enjoy higher-intensity training, while conscientious people are likelier to engage in longer hours of regular physical activity. And people who scored high for 'neuroticism' on a pre-study questionnaire — which the authors associate with emotional instability — are likely to enjoy private and independent exercise programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Former Eagles LB Bryan Braman passes away at age 38
Former Houston Texans and Philadelphia Eagles linebacker Bryan Braman passed away on Thursday after seeking treatment this year for a rare, aggressive form of cancer, according to his agent. He was 38. KPRC in Houston was informed by Braman's agent, Sean Stellato, that the linebacker was "in the fight of his life." J.J. Watt, a teammate of his when they both played for the Houston Texans, donated $10,000 as a show of support. More recently, former Eagles star and FS1 mainstay Emmanuel Acho spoke up after hearing the news. Braman, a former 2011 undrafted rookie free agent, spent the first three years of his career with the Houston Texans. After that, he landed in Philadelphia for the first of two stints with the Birds. According to Braman's GoFundMe page, one set up by his friend, William Jones, the former Eagle underwent multiple "CAR-T cell reprogramming treatment programs in Seattle." As of July 3, $32,000 had been raised. Braman played seven seasons in the NFL, from 2011 to 2017. This article originally appeared on Eagles Wire: Bryan Braman passed away at age 38
Yahoo
15 minutes ago
- Yahoo
Vulcan Value Partners Added its Position in UnitedHealth Group (UNH) in Q2
Investment management company Vulcan Value Partners recently released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The firm does not focus on short-term outcomes, whether positive or negative, and believes it can enhance the potential long-term returns and reduce risk. In the quarter, the Large Cap Composite returned 7.0% net of fees and expenses, the Small Cap Composite returned 6.7% net, the Focus Composite returned 9.5% net, the Focus Plus composite returned 8.8% and the All-Cap Composite returned 8.1% net. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Vulcan Value Partners highlighted stocks such as UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH) is a diversified healthcare company that operates through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments. The one-month return of UnitedHealth Group Incorporated (NYSE:UNH) was -4.79%, and its shares lost 48.98% of their value over the last 52 weeks. On July 16, 2025, UnitedHealth Group Incorporated (NYSE:UNH) stock closed at $292.49 per share, with a market capitalization of $265.329 billion. Cooper Investors Global Equities Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its second quarter 2025 investor letter: "We purchased two positions during the quarter: Ares Management Corp. and UnitedHealth Group Incorporated (NYSE:UNH). We have owned UnitedHealth Group successfully a number of times in our Large Cap portfolio. We are gratified to be able to purchase it in our Focus portfolio. In April, UnitedHealth Group lowered its earnings guidance for the year. In mid-May, UnitedHealth Group withdrew its revised 2025 guidance and announced that its CEO Andrew Witty was resigning. Additionally, headlines and news flow on UnitedHealth Group have remained negative. Over the course of a month, its stock price declined by more than 50%. This spike of volatility gave us the opportunity to follow our discipline and add the company to our portfolio. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) is in 18th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 139 hedge fund portfolios held UnitedHealth Group Incorporated (NYSE:UNH) at the end of the first quarter, which was 150 in the previous quarter. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered UnitedHealth Group Incorporated (NYSE:UNH) and shared the list of stocks on Jim Cramer's radar. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
15 minutes ago
- Yahoo
What Makes IQVIA Holdings (IQV) an Investment Bet?
Investment management company Vulcan Value Partners recently released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The firm does not focus on short-term outcomes, whether positive or negative, and believes it can enhance the potential long-term returns and reduce risk. In the quarter, the Large Cap Composite returned 7.0% net of fees and expenses, the Small Cap Composite returned 6.7% net, the Focus Composite returned 9.5% net, the Focus Plus composite returned 8.8% and the All-Cap Composite returned 8.1% net. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Vulcan Value Partners highlighted stocks such as IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is an analytical technology services and clinical research-providing company to the life sciences industry. The one-month return IQVIA Holdings Inc. (NYSE:IQV) was -2.61%, and its shares lost 29.45% of their value over the last 52 weeks. On July 16, 2025, IQVIA Holdings Inc. (NYSE:IQV) stock closed at $158.64 per share with a market capitalization of $27.445 billion. Vulcan Value Partners stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its second quarter 2025 investor letter: "We purchased two positions during the quarter: UnitedHealth Group Inc. and IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings is a healthcare data and services company, commonly known as a contract research organization, or CRO for short. CROs are hired by sponsors ranging from large pharmaceutical companies to small biotech and medical device companies to support research, development and ultimately the commercialization of drugs, vaccines and devices. IQVIA was formed in 2016 through the merger of Quintiles and IMS Health. The merger combined the strong product development expertise of Quintiles with IMS's rich data assets to support better outcomes for clients. Today, IQVIA is the largest CRO in the world. It works with more than 10,000 customers, including 100% of the top 25 largest pharmaceutical companies, and 75% of the top 80 small and mid-sized pharmaceutical companies. Its sheer size and scale can be seen in the fact that it has helped develop more than 70% of all FDA-approved drugs since its merger. IQVIA is led by a highly aligned and focused management team and Board. The company generates mid-to high single-digit earnings growth, trades at a high single-digit current free cash flow yield and is priced today at a healthy discount to our estimate of fair value. A researcher in a lab with a microscope examining a sample. IQVIA Holdings Inc. (NYSE:IQV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 67 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the first quarter, which was 51 in the previous quarter. IQVIA Holdings Inc. (NYSE:IQV) reported first quarter revenue of $3,829 million, up 2.5% reported, 3.5% at constant currency. While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IQVIA Holdings Inc. (NYSE:IQV) and shared the list of most undervalued NYSE stocks to buy. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
